FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Connolly Thomas					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								(Check all appli Directo		icable) or r (give title		erson(s) to Issuer 10% Owner Other (specify	
	C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 12/04/2013									below) below) SVP, Human Resources				
130 WAVERLY ST.						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE, MA 02139														X	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	State)	(Zip)																
		Tab	le I - N	lon-Deri	vative	e Sec	uriti	es A	cquire	d, D	isposed (of, or B	enefici	ally	Owne	d			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N						Exec if any			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a)			Benefic Owned Report		ies cially Following	Form: Direct (D) or Indirect (I) (Instr. 4) dtion(s)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price			ction(s)			(Instr. 4)
Common Stock 12/04/203						13			M		937	Α	\$53.	.74 5,		,189		D	
Common Stock 12/04/201					2013	13			S ⁽¹⁾		937	D	\$67.38	8(2)(3)		,252		D	
Common Stock															150			I	401(k)
		Т	able II								posed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)) if any		4. Transa Code (8)	action	on of		6. Date Exerci Expiration Da (Month/Day/Yo		isable and	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. I De Se	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amour or Numbe of Shares	r					
Stock Option (right to	\$53.74	12/04/2013	04/2013		M			937	(4)		09/03/2022	Common Stock	937		\$0.00	10,313		D	

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$67.38 (range \$67.00 to \$67.72).
- 3. Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. The option vests in 16 quarterly installments from 09/04/2012.

Remarks:

Kenneth L. Horton, Attorney-In-Fact

12/05/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.